These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 26137785)

  • 21. Influenza viruses: basic biology and potential drug targets.
    Basler CF
    Infect Disord Drug Targets; 2007 Dec; 7(4):282-93. PubMed ID: 18220960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational studies of influenza A virus at three important targets: hemagglutinin, neuraminidase and M2 protein.
    Rungrotmongkol T; Yotmanee P; Nunthaboot N; Hannongbua S
    Curr Pharm Des; 2011; 17(17):1720-39. PubMed ID: 21619529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design.
    Mtambo SE; Amoako DG; Somboro AM; Agoni C; Lawal MM; Gumede NS; Khan RB; Kumalo HM
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraminidase inhibitors as antiviral agents.
    Alymova IV; Taylor G; Portner A
    Curr Drug Targets Infect Disord; 2005 Dec; 5(4):401-9. PubMed ID: 16535861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza virus resistance to neuraminidase inhibitors.
    Samson M; Pizzorno A; Abed Y; Boivin G
    Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
    Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
    ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antivirals for influenza: historical perspectives and lessons learned.
    Hayden FG
    Antiviral Res; 2006 Sep; 71(2-3):372-8. PubMed ID: 16815563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
    Cheng CK; Tsai CH; Shie JJ; Fang JM
    Future Med Chem; 2014 May; 6(7):757-74. PubMed ID: 24941871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.
    Han J; Perez J; Schafer A; Cheng H; Peet N; Rong L; Manicassamy B
    Curr Med Chem; 2018; 25(38):5115-5127. PubMed ID: 28933281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuraminidase inhibitors as anti-influenza virus agents.
    Kim CU; Chen X; Mendel DB
    Antivir Chem Chemother; 1999 Jul; 10(4):141-54. PubMed ID: 10480735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
    Eichelberger MC; Hassantoufighi A; Wu M; Li M
    Virol J; 2008 Sep; 5():109. PubMed ID: 18822145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.
    Pozo F; Lina B; Andrade HR; Enouf V; Kossyvakis A; Broberg E; Daniels R; Lackenby A; Meijer A;
    J Clin Virol; 2013 May; 57(1):5-12. PubMed ID: 23375738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.
    Tumpey TM; García-Sastre A; Mikulasova A; Taubenberger JK; Swayne DE; Palese P; Basler CF
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13849-54. PubMed ID: 12368467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in anti-influenza agents with neuraminidase as target.
    Zhang J; Xu W
    Mini Rev Med Chem; 2006 Apr; 6(4):429-48. PubMed ID: 16613580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate.
    Kim M; Kim SY; Lee HW; Shin JS; Kim P; Jung YS; Jeong HS; Hyun JK; Lee CK
    Antiviral Res; 2013 Nov; 100(2):460-72. PubMed ID: 23954192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Implications of Antiviral Resistance in Influenza.
    Li TC; Chan MC; Lee N
    Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspective of Use of Antiviral Peptides against Influenza Virus.
    Skalickova S; Heger Z; Krejcova L; Pekarik V; Bastl K; Janda J; Kostolansky F; Vareckova E; Zitka O; Adam V; Kizek R
    Viruses; 2015 Oct; 7(10):5428-42. PubMed ID: 26492266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase.
    Xie Y; Gong J; Li M; Fang H; Xu W
    Curr Med Chem; 2011; 18(7):1050-66. PubMed ID: 21254972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacophore model of influenza neuraminidase inhibitors--a systematic review.
    Gong JZ; Liu Y; Xu WF
    Pharmazie; 2009 Oct; 64(10):627-32. PubMed ID: 19947162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.